Temozolomide: Therapeutic limitations in the treatment of adult high-grade gliomas

Expert Review of Neurotherapeutics

Volumn 10, Issue 10, 2010, Pages 1537-1544

  Chamberlain, Marc C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

alkylator based therapy for gliomas; high grade gliomas; temozolomide chemotherapy; temozolomide based chemotherapy

Indexed keywords

BEVACIZUMAB; CARMUSTINE; COTRIMOXAZOLE; DAPSONE; LOMUSTINE; PENTAMIDINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE DURATION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HUMAN; LOW DRUG DOSE; LYMPHOCYTOPENIA; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PALLIATIVE THERAPY; PNEUMOCYSTIS PNEUMONIA; RETREATMENT; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; PALLIATIVE CARE; RECURRENCE; TREATMENT OUTCOME;

EID: 77957979474     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.32     Document Type: Review

References (38)

1. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO Classification of Tumour of the Central Nervous System. Acta Neuropathol. 114(2), 97-109 (2007).
2. Erratum in: Acta Neuropathol. 114(5), 547 (2007).
3. Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J. Neurosurgery 49(3), 333-343 (1978).
4. Fine HA, Dean KB, Loeffler JS et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 72(11), 3367 (1993).
5. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311), 1011-1018 (2002).
6. Spiegel BM, Esrailian E, Laine L Chamberlain MC. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: A meta-analysis. CNS Drugs 21(9), 775-787 (2007). First post-temozolomide meta-analysis of the treatment of high-grade gliomas.
7. Wong ET, Hess KR, Gleason MJ. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. 17(8), 2572-2578 (1999).
8. Stupp R, Mason WP, van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). Practice-changing randomized trial in newly diagnosed patients with glioblastoma (GBM).
9. Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83(5), 588-593 (2000).
10. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005). Companion retrospective trial delineating the value of promoter methylation of the MGMT gene with regards to temozolomide efficacy in newly diagnosed GBM.
11. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol. 17(9), 2762-2771 (1999).
12. Wick WW, Weller M; Neuro-oncology Working Group of the German Cancer Society et al. NOA-04 randomized Phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide. J. Clin. Oncol. 28(15S), LBA2001 (2010). Practice-changing trial in newly diagnosed anaplastic glioma suggesting equi-efficacy for either primary chemotherapy or primary radiotherapy.
13. Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Oncology Group trial 9402. J. Clin. Oncol. 24(18), 2707-2714 (2006). Randomized trial indicating the unique biology and response of 1p19q codeleted anaplastic oligodendroglial tumors.
14. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine and vincristine improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organization for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol. 24(18), 2715-2722 (2006). Randomized trial indicating the unique biology and response of 1p19q codeleted anaplastic oligodendroglial tumors.
15. van den Bent MJ, Chinot O, Boogerd W. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group Phase II Study 26972. Ann. Oncol. 14(4), 599-602 (2003).
16. Triebels VHJM, Taphoorn MJ, Brandes AA. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 63(5), 904-906 (2004).
17. Mirimanoff R-O, Gorlia T, Mason W et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 Phase III randomized trial. J. Clin. Oncol. 24(16), 2563-2569 (2006).
18. Perry JR, Mason WP, Belanger K et al. The temozolomide RESCUE study: A Phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. J. Clin. Oncol. 26(Suppl.), 2010 (2008).
19. Brem SS, Bierman PJ, Black P et al. Central nervous system cancers: Clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 3, 644-690 (2005).
20. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343(19), 1350-1354 (2000).
21. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 20(9), 2388-2399 (2002).
22. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008). Comprehensive characterization of high-grade gliomas genomics.
23. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin. Cancer Res. 5(4), 807-814 (1999).
24. Liu L, Gerson SL. Targeted modulation of MGMT: Clinical implications. Clin. Cancer Res. 12(2), 328-331 (2006).
25. 6-methylguinine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26(25), 4189-4199 (2008).
26. Gerber DE, Grossman SA, Zeltzman M Parisi MA, Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neurooncology 9(1), 47-52 (2007).
27. Grossman SA, Ye X, Lesser G et al. Iatrogenic immunosuppression in patients with newly diagnosed high-grade gliomas. J. Clin. Oncol. 25(18 Suppl.), 2012 (2007).
28. Chamberlain MC, Raizer J. Extended exposure to alkylator chemotherapy: Delayed appearance of myelodysplasia. J. Neuro. Oncol. 93(2), 229-232 (2008).
29. Armstrong TS, Cao Y, Vera E et al. Pharmacoepidemiology of myelotoxicity (TOX) with temozolomide (TMX) in malignant glioma patients. J. Clin. Oncol. 26(15S), S513 (2008).
30. Su YW, Chang MC, Chiang MF, Hsieh RK. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neurooncol. 71(3), 315-318 (2005).
31. Vredenburgh JJ, Desjardin SA, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
32. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70(10), 779-787 (2008).
33. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740-745 (2009). Practice-changing clinical trial in patients with recurrent GBM indicating single-agent efficacy of bevacizumab.
34. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4753-4740 (2009). Practice-changing clinical trial in patients with recurrent GBM indicating single-agent efficacy of bevacizumab with or without irinotecan.
35. Lamborn KR, Yung WK, Chang SM et al. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 10(2), 162-170 (2008).
36. Nabors LB, Mikkelsen T, Rosenfeld SS et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 25(13), 1651-1657 (2007).
37. Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26(34), 5610-5617 (2008).
38. Mrugala M, Chamberlain MC. Mechanism of disease: Temozolomide and glioblastoma - a look to the future. Nat. Clin. Pract. Oncol. 5(8), 476-486 (2008).